Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Network analysis of randomized controlled trials in multiple sclerosis.

Zintzaras E, Doxani C, Mprotsis T, Schmid CH, Hadjigeorgiou GM.

Clin Ther. 2012 Apr;34(4):857-869.e9. doi: 10.1016/j.clinthera.2012.02.018. Epub 2012 Mar 22.

PMID:
22444787
2.

Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.

Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA.

Curr Med Res Opin. 2012 May;28(5):767-80. doi: 10.1185/03007995.2012.681637. Epub 2012 Apr 24.

PMID:
22462530
3.

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.

Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E.

J Clin Pharm Ther. 2013 Dec;38(6):433-9. doi: 10.1111/jcpt.12090. Epub 2013 Aug 20. Review.

PMID:
23957759
4.

Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.

Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A.

Eur J Clin Pharmacol. 2012 Apr;68(4):441-8. doi: 10.1007/s00228-011-1141-1. Epub 2011 Nov 5.

PMID:
22057838
5.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
6.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

7.

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.

O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.

J Med Econ. 2011;14(5):617-27. doi: 10.3111/13696998.2011.602444. Epub 2011 Jul 22.

PMID:
21777161
8.

Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: a network meta-analysis.

Bakalos G, Miligkos M, Doxani C, Mpoulimari I, Rodopoulou P, Zintzaras E.

Cancer Epidemiol. 2013 Oct;37(5):675-82. doi: 10.1016/j.canep.2013.06.008. Epub 2013 Aug 2.

PMID:
23911891
9.

Interferons and natalizumab for multiple sclerosis.

Clar C, Velasco Garrido M, Gericke C, Busse R.

GMS Health Technol Assess. 2008 Oct 1;4:Doc09.

10.

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group.

JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. Erratum in: JAMA Neurol. 2015 Aug;72(8):950.

11.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
12.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

14.

Lessons from randomised direct comparative trials.

Achiron A, Fredrikson S.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24. doi: 10.1016/S0022-510X(09)70007-3. Review.

PMID:
19200860
15.
16.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
17.

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.

Comi G.

Clin Ther. 2009 Jun;31(6):1142-57. doi: 10.1016/j.clinthera.2009.06.007. Review.

PMID:
19695384
19.

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.

Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J.

Mult Scler. 2012 Sep;18(9):1269-77. doi: 10.1177/1352458511435984. Epub 2012 Feb 21.

PMID:
22354739
20.

Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.

Agius M, Meng X, Chin P, Grinspan A, Hashmonay R.

CNS Neurosci Ther. 2014 May;20(5):446-51. doi: 10.1111/cns.12235. Epub 2014 Mar 31.

PMID:
24684973

Supplemental Content

Support Center